Abiologics' Mike Hamill on "Protein Medicines That Biology Can't Get Its Hands On"

As a follow up to our deep dive on D-protein therapeutics, Avak Kahvejian sits down with Abiologics Chief Innovation Officer Mike Hamill for the story behind the data — exploring how AI, protein design, and novel chemistry converged to create a new generation of biologics.